Tirzepatide Outcomes (SURMOUNT-1) The SURMOUNT-1 randomized clinical trial evaluated tirzepatide at three dose levels: 5 mg, 10 mg, and 15 mg weekly in adults with obesity
They protect everything else so the weight you lose is fat, not muscle, vitality, or long-term health
This guide breaks down every meaningful difference between tirzepatide and retatrutide, from receptor pharmacology to clinical trial results, dosing protocols , side effect profiles, and practical availability
TripleHormone-Receptor agonist Retatrutide for Obesity A phase 2 trial
Its best to limit or even avoid caffeine from coffee or and other beverages while taken them and avoid it too close to bedtime. However, weve also included non-stimulant options in our lineup, for those who prefer options without caffeine and other stimulants